Journal Article

Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma

Bruhn, Kevin W., Economou, James S., Dauphine, Christine, Vargas, Hernan I., Haskell, Jacquelyn, Ribas, Antoni, Konishi, Tamiko, Greger, Stephanie, Tsui, Shanli, Narayan, Rupa, Comin-Anduix, Begonya, Bentow, Jason J., Moy, Lauren, Nguyen, Hong, Chang, Pei-Lin, Lee, Diana K., Craft, Noah, Vanchinathan, Veena

2012

Overview

Imiquimod is a synthetic Toll-like receptor 7 (TLR7) agonist approved for the topical treatment of actinic keratoses, superficial basal cell carcinoma, and genital warts. Imiquimod leads to an 80–100% cure rate of lentigo maligna; however, studies of invasive melanoma are lacking. We conducted a pilot study to characterize the local, regional, and systemic immune responses induced by imiquimod in patients with high-risk melanoma. After treatment of the primary melanoma biopsy site with placebo or imiquimod cream, we measured immune responses in the treated skin, sentinel lymph nodes (SLNs), and peripheral blood. Treatment of primary melanomas with 5% imiquimod cream was associated with an increase in both CD4+ and CD8+ T cells in the skin, and CD4+ T cells in the SLN. Most of the CD8+ T cells in the skin were CD25 negative. We could not detect any increases in CD8+ T cells specifically recognizing HLA-A*0201-restricted melanoma epitopes in the peripheral blood. The findings from this small pilot study demonstrate that topical imiquimod treatment results in enhanced local and regional T-cell numbers in both the skin and SLN. Further research into TLR7 immunomodulating pathways as a basis for effective immunotherapy against melanoma in conjunction with surgery is warranted.

• Publisher: Elsevier Inc,Nature Publishing Group,Elsevier Limited
• Subject: Administration, Topical / Adult / Aminoquinolines - administration & dosage / Antineoplastic Agents - administration & dosage / Biological and medical sciences / Combined Modality Therapy / Dermatology / Female / Humans / Imiquimod / Immunologic Factors - administration & dosage / Male / Medical sciences / Melanoma - drug therapy / Melanoma - epidemiology / Melanoma - surgery / Pilot Projects / Preoperative Care - methods / Prospective Studies / Risk Factors / Skin - drug effects / Skin - pathology / Skin Neoplasms - drug therapy / Skin Neoplasms - epidemiology / Skin Neoplasms - surgery / T-Lymphocytes - immunology / Toll-Like Receptor 7 - immunology / Toll-Like Receptor 7 - metabolism / Treatment Outcome / Tumors of the skin and soft tissue. Premalignant lesions